Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Average PT from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned a consensus recommendation of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $56.33.

A number of brokerages recently commented on AGIO. Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Scotiabank lifted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Raymond James reissued an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.93% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC increased its stake in Agios Pharmaceuticals by 1.1% during the 2nd quarter. Farallon Capital Management LLC now owns 5,654,502 shares of the biopharmaceutical company’s stock valued at $243,822,000 after buying an additional 63,900 shares during the period. State Street Corp grew its position in Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after buying an additional 216,484 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals during the third quarter worth $97,199,000. Geode Capital Management LLC raised its holdings in Agios Pharmaceuticals by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after buying an additional 6,101 shares during the period. Finally, Marshall Wace LLP lifted its stake in Agios Pharmaceuticals by 307.8% during the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after buying an additional 855,739 shares in the last quarter.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO opened at $35.12 on Friday. The firm has a 50-day moving average of $47.15 and a two-hundred day moving average of $45.63. The stock has a market cap of $2.00 billion, a P/E ratio of 3.09 and a beta of 0.87. Agios Pharmaceuticals has a 1-year low of $20.96 and a 1-year high of $62.58.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.